Abstract: Methods and compositions to restore function to acidified T cells are provided. The methods comprise administering urease to the T cells. Compositions comprise urease.

Abstract: This disclosure provides antibody-urease conjugates having therapeutic utility. More specifically, the disclosure relates to therapeutic conjugates that are prepared by conjugating one or more antibodies to urease, and their use in the diagnosis and treatment of disease.

Abstract: Pharmaceutical compositions comprising antibody-urease conjugates and substantially free of unconjugated urease are disclosed. These compositions are prepared by a method that does not require chromatographic purification. These pharmaceutical compositions have utility in the treatment of cancer by antibody-directed enzyme prodrug therapy wherein the urease converts endogenous urea into ammonia in situ to induce cytotoxicity.

Abstract: Compositions and methods for treating cancer in humans are provided using CARs. The invention includes engineered CARs (chimeric receptor antigens) and genetically modified immune cells that express such a CAR with a high affinity for VEGFR. More specifically, the cells are CAR-T cells recognizing VEGFR-2 on solid tumors, uses thereof, compositions thereof and methods of making. The invention includes therapeutic methods to treat VEGFR-2 dependent cancers targeting tumor angiogenesis. A chimeric antigen receptor (CAR) that binds to VEGFR-2, an epitope or fragment thereof, or a variant thereof.

Abstract: A chimeric antigen receptor (CAR) that binds to CEACAM6, an epitope or fragment thereof, or a variant thereof.

Abstract: This invention relates to a hybrid composite polymer matrix, assembled by integrating two polymer networks, as an anti-scratch coating for automobiles. The two types of particulate silane cross-liners are utilized to construct two respective hybrid polymer networks with a unique chain-from-particle structure. At least one hybrid network is a covalently bound network that is interlocked with at least one physically bound hybrid network.

Abstract: Methods and compositions to restore function to acidified T cells are provided. The methods comprise administering urease to the T cells. Compositions comprise urease.

Abstract: Methods and compositions to restore function to acidified T cells are provided. The methods comprise administering urease to the T cells. Compositions comprise urease.

Abstract: This invention relates to a hybrid composite polymer matrix, assembled by integrating two polymer networks, as an anti-scratch coating for automobiles. The two types of particulate silane cross-liners are utilized to construct two respective hybrid polymer networks with a unique chain-from-particle structure. At least one hybrid network is a covalently bound network that is interlocked with at least one physically bound hybrid network.

Abstract: This invention relates to a hybrid composite polymer matrix, assembled by integrating two polymer networks, as an anti-scratch coating for automobiles. The two types of particulate silane cross-liners are utilized to construct two respective hybrid polymer networks with a unique chain-from-particle structure. At least one hybrid network is a covalently bound network that is interlocked with at least one physically bound hybrid network.

Abstract: The invention relates to a film comprising an interpenetrating network, its uses and processes for making the same. The film produced displays good durability, chemical resistance and transparency. The film is produced from an interpenetrating network formed as a colloidal suspension in an organic solvent and a particulate solid.

Abstract: A conjugate comprising an anti-VEGFR-2 antibody moiety conjugated to a urease moiety is described.

Abstract: Single domain anti-VEGFR-2 antibodies and fragments thereof and variants thereof and uses thereof, for example, for use to inhibit/decrease angiogenesis and induce tumor regression.

Abstract: Compositions and methods for treating cancer in humans are provided using CARs. The invention includes engineered CARs (chimeric receptor antigens) and genetically modified immune cells that express such a CAR with a high affinity for VEGFR. More specifically, the cells are CAR-T cells recognizing VEGFR-2 on solid tumors, uses thereof, compositions thereof and methods of making. The invention includes therapeutic methods to treat VEGFR-2 dependent cancers targeting tumor angiogenesis. A chimeric antigen receptor (CAR) that binds to VEGFR-2, an epitope or fragment thereof, or a variant thereof.

Abstract: Methods and compositions to restore function to acidified T cells are provided. The methods comprise administering urease to the T cells. Compositions comprise urease.

Abstract: A chimeric antigen receptor (CAR) that binds to CEACAM6, an epitope or fragment thereof, or a variant thereof.

Abstract: Pharmaceutical compositions comprising antibody-urease conjugates and substantially free of unconjugated urease are disclosed. These compositions are prepared by a method that does not require chromatographic purification. These pharmaceutical compositions have utility in the treatment of cancer by antibody-directed enzyme prodrug therapy wherein the urease converts endogenous urea into ammonia in situ to induce cytotoxicity.

Abstract: This invention relates to a hybrid composite polymer matrix, assembled by integrating two polymer networks, as an anti-scratch coating for automobiles. The two types of particulate silane cross-liners are utilized to construct two respective hybrid polymer networks with a unique chain-from-particle structure. At least one hybrid network is a covalently bound network that is interlocked with at least one physically bound hybrid network.

Abstract: Human prion protein, PrP, selectively presents the epitope MDEYSNQNN (SEQ ID No. 14) when PrP misfolds. The misfolded form of human PrP is associated with various disease states. The present invention provides an antibody useful to detect and treat such diseases, including cancer such as ovarian cancer and lymphomas, and transmissible spongiform encephalopathies such as CJD. Also provided is an immunoconjugate in which the antibody is conjugated with urease as cytotoxin.

Abstract: Human prion protein, PrP, selectively presents the epitope MDEYSNQNN (SEQ ID No. 14) when PrP misfolds. The misfolded form of human PrP is associated with various disease states. The present invention provides an antibody useful to detect and treat such diseases, including cancer such as ovarian cancer and lymphomas, and transmissible spongiform encephalopathies such as CJD. Also provided is an immunoconjugate in which the antibody is conjugated with urease as cytotoxin.